

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.7824 - VITA CENTRAL EUROPE / WALMARK

SECTION 1.2

Description of the concentration

1. The notified transaction involves the acquisition of control of WALMARK, a.s. (“**Walmark**”) by Vita Central Europe B.V. (“**Vita Central**”) within the meaning of Article 3(1)(b) of the Merger Regulation (the “**Transaction**”).
2. Walmark is a consumer healthcare company headquartered in the Czech Republic. The core business of Walmark is the production and distribution of dietary supplements and OTC pharmaceuticals. Walmark is active primarily in Central and Eastern Europe.
3. Vita Central is part of a private equity group that invests in a number of sectors, including healthcare, retail, FMCG, business services, logistics, pay TV, telecommunications and leisure, in Central and Eastern Europe and in Turkey.
4. The Transaction will not give rise to any direct horizontal overlaps. The only possible vertical link relates to Poland, where Zabka Polska (“**Zabka**”), one of the portfolio companies controlled by the same fund as Vita Central, operates a chain of convenience stores that distributes a minimal number of everyday healthcare products. Nonetheless, Walmark’s products do not constitute important input to Zabka’s convenience stores.
5. As Walmark is jointly controlled by Vita Central and another shareholder already prior to the Transaction, and given the limited overlaps, the Transaction will not result in any change to the competitive situation.